Cisplatin- vs. oxaliplatin-based radiosensitizing chemotherapy for squamous cell carcinoma of the esophagus

MLA

Bernhard Haller, et al. “Cisplatin- vs. Oxaliplatin-Based Radiosensitizing Chemotherapy for Squamous Cell Carcinoma of the Esophagus.” Strahlentherapie Und Onkologie, vol. 190, Apr. 2014, pp. 987–92. EBSCOhost, https://doi.org/10.1007/s00066-014-0661-x.

APA

Bernhard Haller, Florian Lordick, Hans Geinitz, J. Theisen, Arif Deniz Ordu, Khashayar Fakhrian, V. Bisof, & Michael Molls. (2014). Cisplatin- vs. oxaliplatin-based radiosensitizing chemotherapy for squamous cell carcinoma of the esophagus. Strahlentherapie Und Onkologie, 190, 987–992. https://doi.org/10.1007/s00066-014-0661-x

Chicago

Bernhard Haller, Florian Lordick, Hans Geinitz, J. Theisen, Arif Deniz Ordu, Khashayar Fakhrian, V. Bisof, and Michael Molls. 2014. “Cisplatin- vs. Oxaliplatin-Based Radiosensitizing Chemotherapy for Squamous Cell Carcinoma of the Esophagus.” Strahlentherapie Und Onkologie 190 (April): 987–92. doi:10.1007/s00066-014-0661-x.